Claims
- 1. A method for treating excitotoxicity resulting from over-stimulation of the NMDA receptor which comprises administering to a patient in need thereof a therapeutically effective amount of an active agent selected from the group consisting of Conantokin-T and pharmaceutically acceptable salts thereof, wherein Conantokin-T has the formula Gly-Glu-Xaa1-Xaa2-Tyr-Gln-Lys-Met-Leu-Xaa1-Asn-Leu-Arg-Xaa1-Ala-Glu-Val-Lys-Lys-Asn-Ala (SEQ ID NO:2)where Xaa1 and Xaa2 are each γ-carboxy-glutamic acid.
- 2. The method of claim 1, wherein said excitotoxicity is associated with epilepsy or epileptic seizure.
- 3. The method of claim 1, wherein said excitotoxicity is associated with brain ischemia caused by stroke or traumatic injury.
- 4. The method of claim 1, wherein said treatment protects neurons from excitotoxic death.
- 5. A method for treating a neuropsychopharmacological disorder resulting from over-stimulation of the NMDA receptor which comprises administering to a patient in need thereof a therapeutically effective amount of selected from the group consisting of Conantokin-T and pharmaceutically acceptable salts thereof an active agent, wherein Conantokin-T has the formula Gly-Glu-Xaa1-Xaa2-Tyr-Gln-Lys-Met-Leu-Xaa1-Asn-Leu-Arg-Xaa1-Ala-Glu-Val-Lys-Lys-Asn-Ala (SEQ ID NO:2) where Xaa1 and Xaa2 are each γ-carboxy-glutamic acid.
- 6. The method of claim 5, wherein said disorder is selected from the group consisting of chemical toxicity, neurodegenerative disorder, mood disorder and depression.
- 7. The method of claim 6, wherein said disorder is a mood disorder selected from the group consisting of bipolar disorder, dysthymia and seasonal affective disorder.
- 8. The method of claim 6, wherein said disorder is a neurodegenerative disorder selected from the group consisting of Huntington's disease, Parkinson's disease and Alzheimer's disease.
- 9. The method of claim 6, wherein said disorder is chemical toxicity selected from the group consisting of substance tolerance and addiction.
- 10. A method for treating excitotoxicity resulting from over-stimulation of the NMDA receptor which comprises administering to a patient in need thereof a therapeutically effective amount of an active agent selected from the group consisting of Conantokin-T, Conantokin-G, a Conantokin-G derivative and pharmaceutically acceptable salts thereof, wherein Conantokin-T has the formula Gly-Glu-Xaa1-Xaa2-Tyr-Gln-Lys-Met-Leu-Xaa1-Asn-Leu-Arg-Xaa1-Ala-Glu-Val-Lys-Lys-Asn-Ala (SEQ ID NO:2) and Conantokin-G has the formula Gly-Glu-Xaa1-Xaa2-Leu-Gln-Xaa1-Asn-Gln-Xaa1-Leu-Ile-Arg-Xaa1-Lys-Ser-Asn (SEQ ID NO: 1) where Xaa1 and Xaa2 are each γ-carboxy-glutamic acid and wherein said Conantokin-G derivative is an antagonist of the NMDA receptor and has the following formula:
CROSS-REFERENCE OF RELATING APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/553,042, filed Apr. 20, 2000, which is a continuation of U.S. application Ser. No. 09/146,269, filed Sep. 3, 1998, which is a divisional of U.S. application Ser. No. 08/413,490, filed Mar. 30, 1995, which is a continuation-in-part of U.S. application Ser. No. 08/323,436, filed Oct. 14, 1994, which is a continuation-in-part of U.S. application Ser. No. 07/952,818, filed Sep. 28, 1992, the disclosures of which are incorporated herein by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08413490 |
Mar 1995 |
US |
Child |
09146269 |
Sep 1998 |
US |
Continuations (2)
|
Number |
Date |
Country |
Parent |
09553042 |
Apr 2000 |
US |
Child |
10302971 |
Nov 2002 |
US |
Parent |
09146269 |
Sep 1998 |
US |
Child |
09553042 |
Apr 2000 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
08323436 |
Oct 1994 |
US |
Child |
08413490 |
Mar 1995 |
US |
Parent |
07952818 |
Sep 1992 |
US |
Child |
08323436 |
Oct 1994 |
US |